Skip to main
SKIN

SKIN Stock Forecast & Price Target

SKIN Analyst Ratings

Based on 4 analyst ratings
Hold
Strong Buy 25%
Buy 0%
Hold 75%
Sell 0%
Strong Sell 0%

Bulls say

SkinHealth Systems is a global medical aesthetics company that offers a diverse portfolio of clinically validated solutions, including the popular brands Hydrafacial and SkinStylus. With a highly recurring revenue model and a growing active installed base, the company is well-positioned for sustained growth. However, capital constraints, lower consumables utilization, and a challenging market environment may continue to hinder short-term performance. The company should focus on utilizing boosters, improving treatment frequency, and expanding its global footprint to drive future growth.

Bears say

SkinHealth Systems is facing intensified competition in its market, leading to pressure on sales and profitability. Despite management's execution on strategic priorities, the guidance for the current quarter and full fiscal year implies continued weakness in revenue, indicating limited evidence of a sustainable return to growth. Additionally, ongoing litigation and an SEC investigation may weigh on the company's cash flow and financial performance going forward. As a result, the financial analyst has a negative outlook on the company's stock.

SKIN has been analyzed by 4 analysts, with a consensus rating of Hold. 25% of analysts recommend a Strong Buy, 0% recommend Buy, 75% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of The Beauty Health Company and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About The Beauty Health Company (SKIN) Forecast

Analysts have given SKIN a Hold based on their latest research and market trends.

According to 4 analysts, SKIN has a Hold consensus rating as of Sep 22, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $1.38, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $1.38, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

The Beauty Health Company (SKIN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.